产品编号：GM-87846AB
产品名称：Anti-CEACAM5-DM4(Dar4)[Tusamitamab ravtansine]
目录价：询价
产品编号：GM-87846AB
产品名称：Anti-CEACAM5-DM4(Dar4)[Tusamitamab ravtansine]
目录价：询价
GM-87846AB-100 100μg
GM-87846AB-1mg 1mg
Expression System CHO
Purity >95% as determined by SDS-PAGE
Aggregation < 5% as determined by SEC-HPLC
Drug-to-Antibody Ratio (DAR) 3.0-4.0
Endotoxin <1 EU/mg
Sterility 0.22 μm Filtered
Target CEACAM5
Clone Tusamitamab ravtansine
Alternative Names CD66e, CEA
Source/lsotype Monoclonal Human IgG1, kappa
Application Positive control of Cytotoxicity Assay
Description Tusamitamab ravtansine (SAR408701) is a novel antibody-drug conjugate (ADC) targeting CEA (Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5, also known as CD66e). The drug specifically binds to CEA-expressing tumor cells through its chimeric monoclonal antibody and is subsequently internalized into the cells, where it releases the conjugated cytotoxic molecule DM4 (ravtansine, a derivative of an anti-microtubule agent). DM4 disrupts microtubule function, blocks mitosis, and induces tumor cell apoptosis. Tusamitamab ravtansine combines the benefits of targeted therapy and chemotherapy, enhancing treatment precision while significantly reducing systemic toxicity and off-target effects.
Formulation Phosphate-buffered solution, pH 7.2-7.4.
Storage temp. Store at +4°C short term. Store at -80°C for 36 months, avoiding freeze/thaw cycles.
产品编号：GM-87846AB
产品名称：Anti-CEACAM5-DM4(Dar4)[Tusamitamab ravtansine]
目录价：询价
产品编号：GM-87846AB
产品名称：Anti-CEACAM5-DM4(Dar4)[Tusamitamab ravtansine]
目录价：询价
GM-87846AB-100 100μg
GM-87846AB-1mg 1mg
GM-87846AB-100 100μg
GM-87846AB-1mg 1mg
Expression System CHO
Purity >95% as determined by SDS-PAGE
Aggregation < 5% as determined by SEC-HPLC
Drug-to-Antibody Ratio (DAR) 3.0-4.0
Endotoxin <1 EU/mg
Sterility 0.22 μm Filtered
Target CEACAM5
Clone Tusamitamab ravtansine
Alternative Names CD66e, CEA
Source/lsotype Monoclonal Human IgG1, kappa
Application Positive control of Cytotoxicity Assay
Description Tusamitamab ravtansine (SAR408701) is a novel antibody-drug conjugate (ADC) targeting CEA (Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5, also known as CD66e). The drug specifically binds to CEA-expressing tumor cells through its chimeric monoclonal antibody and is subsequently internalized into the cells, where it releases the conjugated cytotoxic molecule DM4 (ravtansine, a derivative of an anti-microtubule agent). DM4 disrupts microtubule function, blocks mitosis, and induces tumor cell apoptosis. Tusamitamab ravtansine combines the benefits of targeted therapy and chemotherapy, enhancing treatment precision while significantly reducing systemic toxicity and off-target effects.
Formulation Phosphate-buffered solution, pH 7.2-7.4.
Storage temp. Store at +4°C short term. Store at -80°C for 36 months, avoiding freeze/thaw cycles.
Expression System CHO
Purity >95% as determined by SDS-PAGE
Aggregation < 5% as determined by SEC-HPLC
Drug-to-Antibody Ratio (DAR) 3.0-4.0
Endotoxin <1 EU/mg
Sterility 0.22 μm Filtered
Target CEACAM5
Clone Tusamitamab ravtansine
Alternative Names CD66e, CEA
Source/lsotype Monoclonal Human IgG1, kappa
Application Positive control of Cytotoxicity Assay
Description Tusamitamab ravtansine (SAR408701) is a novel antibody-drug conjugate (ADC) targeting CEA (Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5, also known as CD66e). The drug specifically binds to CEA-expressing tumor cells through its chimeric monoclonal antibody and is subsequently internalized into the cells, where it releases the conjugated cytotoxic molecule DM4 (ravtansine, a derivative of an anti-microtubule agent). DM4 disrupts microtubule function, blocks mitosis, and induces tumor cell apoptosis. Tusamitamab ravtansine combines the benefits of targeted therapy and chemotherapy, enhancing treatment precision while significantly reducing systemic toxicity and off-target effects.
Formulation Phosphate-buffered solution, pH 7.2-7.4.
Storage temp. Store at +4°C short term. Store at -80°C for 36 months, avoiding freeze/thaw cycles.
